QSC301361

QSC301361 is an undisclosed clinical-stage drug candidate developed by IFM Management, Inc. (an affiliate of IFM Therapeutics). The compound is being evaluated in a Phase I clinical trial in the United Kingdom (ISRCTN24628458) to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. Due to commercial sensitivity, the sponsor has deferred the public disclosure of the trial's full protocol details, intervention, eligibility criteria, and endpoints for up to 30 months after trial completion. Given IFM Therapeutics' focus, the candidate is likely a small molecule modulator targeting the innate immune system, such as the NLRP3 inflammasome, cGAS, or STING pathways.